Generation of Type I interferons (IFNs) occurs downstream of a multitude of immunologic stimuli. The production of these cytokines can be either a positive prognostic, as in defensive immunity against a pathogenic insult, or a negative prognostic, as in promotion of autoimmunity.
In humans, the designation "IFN-Alpha" is used to represent a family of proteins comprised of at least 12 highly homologous protein subtypes that exhibit diverse biologic activities. IFN-Alpha can be used as a therapeutic agent in disease treatment regimens, as a downstream readout of the effectiveness of several drug therapies, and as a marker of pathology in human clinical and preclinical studies.
PBL's Human IFN-Alpha ELISA kits are in the forefront of providing accurate quantitation of IFN-Alpha. Below is a quick view of these kits' IFN-Alpha subtype specificities. For more detailed information such as LLOQs and LLODs of the All-Subtype VeriKine-HS kits, please visit individual product pages.
| IFN | Cat. # 41115 All-Subtype Serum | Cat. # 41135 All-Subtype TCM | Cat. # 41110 Multi-Subtype Serum | Cat. # 41105 Multi-Subtype TCM | Cat. # 41100 TCM |
| IFN-αA | +++ | +++ | ++ | ++ | ++ |
| IFN-α2 | +++ | +++ | ++ | ++ | ++ |
| IFN-αA/D | +++ | +++ | ++ | ++ | ++ |
| IFN-αB2 | +++ | +++ | ++ | ++ | - |
| IFN-αC | +++ | +++ | ++ | ++ | + |
| IFN-αD | +++ | +++ | ++ | ++ | ++ |
| IFN-αF | +++ | +++ | - | - | - |
| IFN-αG | +++ | +++ | ++ | ++ | + |
| IFN-αH | +++ | +++ | ++ | ++ | - |
| IFN-αI | +++ | +++ | ++ | ++ | + |
| IFN-αJ1 | +++ | +++ | ++ | ++ | + |
| IFN-αK | +++ | +++ | ++ | ++ | ++ |
| IFN-α1 | +++ | +++ | ++ | ++ | ++ |
| IFN-α4a | +++ | +++ | + | + | + |
| IFN-αWA | +++ | +++ | ++ | ++ | + |
| IFN-β | - | - | - | - | - |
| IFN-γ | - | - | - | - | - |
| IFN-ω | - | - | - | - | - |
| Rhesus IFN-α2 | + | + | +/- | +/- | + |
Key:
+++ Very Good
++ Good
+ Moderate
- Not at all
+/- Nominal